Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries.

Viljoen L, Draper HR, Castillo-Carandang NT, Suryavanshi N, Marthinus A, Cheong AMA, Ocampo JDD, Dhumal G, Bagchi S, Wademan DT, Kinikar A, Paradkar M, Frias MVG 4th, Casalme DJO, Hesseling AC, Garcia-Prats AJ, Palmer M, Hoddinott G

Open source

DOI
10.5588/ijtldopen.25.0309
Published
2025 Aug
Container
IJTLD open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.5588/ijtldopen.25.0309,
  title = {Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries.},
  author = {Viljoen L and Draper HR and Castillo-Carandang NT and Suryavanshi N and Marthinus A and Cheong AMA and Ocampo JDD and Dhumal G and Bagchi S and Wademan DT and Kinikar A and Paradkar M and Frias MVG 4th and Casalme DJO and Hesseling AC and Garcia-Prats AJ and Palmer M and Hoddinott G},
  year = {2025},
  journal = {IJTLD open},
  doi = {10.5588/ijtldopen.25.0309},
  url = {https://doi.org/10.5588/ijtldopen.25.0309}
}

RIS

TY  - JOUR
TI  - Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries.
AU  - Viljoen L
AU  - Draper HR
AU  - Castillo-Carandang NT
AU  - Suryavanshi N
AU  - Marthinus A
AU  - Cheong AMA
AU  - Ocampo JDD
AU  - Dhumal G
AU  - Bagchi S
AU  - Wademan DT
AU  - Kinikar A
AU  - Paradkar M
AU  - Frias MVG 4th
AU  - Casalme DJO
AU  - Hesseling AC
AU  - Garcia-Prats AJ
AU  - Palmer M
AU  - Hoddinott G
PY  - 2025
JO  - IJTLD open
DO  - 10.5588/ijtldopen.25.0309
UR  - https://doi.org/10.5588/ijtldopen.25.0309
ER  - 

APA

L, V., HR, D., NT, C., N, S., A, M., AMA, C., JDD, O., G, D., S, B., DT, W., A, K., M, P., 4th, F. M., DJO, C., AC, H., AJ, G., M, P., & G, H. (2025). Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries.. IJTLD open. https://doi.org/10.5588/ijtldopen.25.0309

Source records